Ambu A/S (CPH:AMBUB), a developer, producer and marketer of life-saving equipment, announced on Friday that it has agreed on terms to enter into a partnership with Cook Medical (Cook) under which Cook will distribute Ambu's single-use, disposable duodenoscope in the US, following FDA clearance.
This duodenoscope is currently being developed by Ambu to help address infections caused by cross-contamination. Ambu is currently pursuing regulatory clearance from the US FDA for its single-use duodenoscope. These products are currently not available for sale in the US. Expected release for sale is before end of September 2020.
Since 2015, US regulatory authorities have increased their focus on endoscope cross-contamination, particularly reusable endoscopes for gastrointestinal use.
Reportedly, the use of reusable endoscopes can pose a contamination risk to patients because the devices are difficult to reprocess between uses. Alternatively, single-use scopes could have a significant impact on device-related infections and improve hospital workflows because they do not require cleaning or repair.
The company added that, together with Cook Medical, it plans to bring single-use endoscopes to patients undergoing ERCP procedures, to reduce the risk of serious cross-contaminations.
According to Ambu, no further details about the agreement will be disclosed at this time, but the agreement is not expected to have any impact on the outlook for Ambu concerning growth, earnings or free cash flows towards September 2020.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial